New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Haitang Yang1, Shun-Qing Liang1,2, Ralph A Schmid1
1Department of General Thoracic Surgery, Department of BioMedical Research, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Abstract:
In non-small cell lung cancer (NSCLC), the most frequent oncogenic mutation in western countries is KRAS, for which, however, there remains no clinically approved targeted therapies. Recent progress on high biological heterogeneity including diverse KRAS point mutations, varying dependence on mutant KRAS, wide spectrum of other co-occurring genetic alterations, as well as distinct cellular status across the epithelial-to-mesenchymal transition (EMT), has not only deepened our understanding about the pathobiology of KRAS-mutant NSCLC but also brought about unprecedented new hopes for precision treatment of patients. In this review, we provide an update on the most recent advances in KRAS-mutant lung cancer, with a focus on mechanistic insights into tumor heterogeneity, the potential clinic implications and new therapies on horizons tailored for KRAS-mutant lung cancer.
Insights
Targeted therapies for KRAS-mutant non-small cell lung cancer (NSCLC) are emerging. Understanding tumor heterogeneity and new treatment strategies offers hope for precision medicine in NSCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- KRAS mutations are common in non-small cell lung cancer (NSCLC), but targeted therapies are lacking.
- Tumor heterogeneity, including diverse KRAS mutations, co-occurring alterations, and epithelial-to-mesenchymal transition (EMT) status, complicates treatment.
- Recent advances deepen the understanding of KRAS-mutant NSCLC pathobiology.
Purpose of the Study:
- To review recent advances in KRAS-mutant lung cancer.
- To focus on mechanistic insights into tumor heterogeneity.
- To discuss potential clinical implications and emerging therapies for KRAS-mutant NSCLC.
Main Methods:
- Literature review of recent scientific publications.
- Analysis of mechanistic insights into tumor heterogeneity in KRAS-mutant NSCLC.
- Discussion of clinical implications and novel therapeutic strategies.
Main Results:
- Significant progress has been made in understanding the biological heterogeneity of KRAS-mutant NSCLC.
- Diverse KRAS mutations, varying mutant KRAS dependence, co-occurring genetic alterations, and EMT status contribute to tumor complexity.
- These insights are paving the way for new, tailored treatment approaches.
Conclusions:
- Advances in understanding KRAS-mutant NSCLC heterogeneity offer new hope for precision treatment.
- Emerging therapies targeting specific molecular alterations and cellular states are on the horizon.
- Further research into tumor biology is crucial for developing effective therapies for this challenging cancer.
